ArticleEClinicalMedicine2024
Equity impact of HPV vaccination on lifetime projections of cervical cancer burden among cohorts in 84 countries by global, regional, and income levels, 2010-22: a modelling study.
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Uptake and determinants of HPV vaccination in South Asia: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Analyzing and forecasting global cervical cancer burden based on WHO's elimination strategy: insights and projections from a 1990-2021 global burden of disease (GBD) study covering 204 countries and territories.Journal of advanced research · 2026Article
- Incidence, recurrence, and determinants of sexually transmitted infections among people with HIV: a multicenter cohort study in China, 2010-2024, with implications for integrated HIV-STI prevention across the Western Pacific.The Lancet regional health. Western Pacific · 2026Article
- Global Comparative Review of Guidelines for Cervical Adenocarcinoma In Situ.Life (Basel, Switzerland) · 2026Review
- Temporal Trends in Cancer Burden and 27 Subtypes Among Women of Childbearing Age Globally from 1990 to 2021.International journal of women's health · 2026Article
- Review
- HPV vaccination and cervical cancer control in Georgia: evidence and projections.BMC public health · 2025Article
- Strategic implementation of HPV vaccination to eliminate cervical cancer in Georgia.Public health in practice (Oxford, England) · 2025Article
- Revisiting HPV vaccination post-COVID: geopolitical, sociocultural, and ethical disparities in global health.International journal for equity in health · 2025Review
- Wealth, health expenditure and cancer: an econometric analysis for European countries.Health economics review · 2025Article
- Global Estimates of the HPV-related, Noncervical Cancer Burden in People With HIV and AIDS and the Potential Effect of Improved HPV Vaccine Coverage in This Population: A Systematic Review, Meta-analysis and Modeling Study.Open forum infectious diseases · 2025Article
- Challenges in Expanding Access to the HPV Vaccine Among Schooling Girls: A Mixed-Methods Study from Indonesia.Vaccines · 2025Article
- Development of an innovative approach for early diagnosis of cervical cancer using TCR‑like antibodies targeting HPV18 E6 and E7 peptides.Molecular medicine reports · 2025Article
- Long-term efficacy and immunopersistence of anThe Lancet regional health. Western Pacific · 2025Article
- MCMC-Driven mathematical modeling of the impact of HPV vaccine uptake in reducing cervical cancer.Scientific African · 2025Article
- Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use.Signal transduction and targeted therapy · 2025Review
- What cancers explain the growing rural-urban gap in human papillomavirus-associated cancer incidence?The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2025Article
- Pathways and processes to adopting or switching to a single-dose HPV vaccination schedule in low- and middle-income countries: a qualitative study.PLOS global public health · 2025Article
- Coculture of tumor organoids with pathogenic microorganisms: a novel system to mimicFrontiers in cellular and infection microbiology · 2025Review
- Global burden of cancer in women, 1990-2021: a systematic analysis from the GBD 2021 study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: While human papillomavirus (HPV) vaccines have been available since 2006, the coverage has varied among countries. Our aim is to analyse the equity impact of HPV vaccination on the lifetime projections of cervical cancer burden among vaccinated cohorts of 2010-22 in 84 countries. Methods: We used WHO and UNICEF estimates of national immunisation coverage for HPV vaccination in 84 countries during 2010-22. We used PRIME (Papillomavirus Rapid Interface for Modelling and Economics) to estimate the lifetime health impact of HPV vaccination on cervical cancer burden in terms of deaths, cases, and disability-adjusted life years (DALYs) averted by vaccination in their respective countries. We generated concentration indices and curves to assess the equity impact of HPV vaccination across 84 countries. Findings: The health impact of HPV vaccination varied across the 84 countries and ranged from Switzerland to Tanzania at 2 to 34 deaths, 4 to 47 cases, and 40 to 735 DALYs averted per 1000 vaccinated adolescent girls over the lifetime of the vaccinated cohorts of 2010-22. The concentration index for the distribution of average coverage during 2010-22 among the 84 countries ranked by vaccine impact was 0.33 (95% CI: 0.27-0.40) and highlights the wide inequities in HPV vaccination coverage. Interpretation: Our findings suggested that countries with a relatively higher cervical cancer burden and thereby a relatively higher need for HPV vaccination had relatively lower coverage during 2010-22. Further, there were significant inequities in HPV vaccination coverage within the Americas, Europe, and Western Pacific regions, and in high- and low-income countries with a pro-advantaged and regressive distribution favouring countries with lower vaccine impact. Funding: Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.